Free Trial
OTCMKTS:BVNRY

Bavarian Nordic A/S (BVNRY) Stock Price, News & Analysis

Bavarian Nordic A/S logo
$8.50 0.00 (0.00%)
As of 05/23/2025

About Bavarian Nordic A/S Stock (OTCMKTS:BVNRY)

Key Stats

Today's Range
$8.50
$8.50
50-Day Range
$6.84
$8.63
52-Week Range
$6.60
$14.60
Volume
14 shs
Average Volume
7,996 shs
Market Capitalization
$2.01 billion
P/E Ratio
12.32
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bavarian Nordic A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.

Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.

The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.

The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. 
Receive BVNRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bavarian Nordic A/S and its competitors with MarketBeat's FREE daily newsletter.

BVNRY Stock News Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
Bavarian Nordic Shares Jump on Earnings Beat
See More Headlines

BVNRY Stock Analysis - Frequently Asked Questions

Bavarian Nordic A/S's stock was trading at $8.7060 at the start of the year. Since then, BVNRY stock has decreased by 2.4% and is now trading at $8.50.
View the best growth stocks for 2025 here
.

Bavarian Nordic A/S (OTCMKTS:BVNRY) issued its quarterly earnings results on Friday, May, 9th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $189.89 million for the quarter. Bavarian Nordic A/S had a net margin of 18.33% and a trailing twelve-month return on equity of 10.65%.

Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/09/2025
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:BVNRY
CIK
N/A
Employees
1,379
Year Founded
1994

Profitability

Trailing P/E Ratio
12.32
Forward P/E Ratio
12.69
P/E Growth
N/A
Net Income
$214.20 million
Pretax Margin
18.51%

Debt

Sales & Book Value

Annual Sales
$1.02 billion
Cash Flow
$2.04 per share
Price / Cash Flow
4.17
Book Value
$6.41 per share
Price / Book
1.33

Miscellaneous

Free Float
N/A
Market Cap
$2.01 billion
Optionable
Not Optionable
Beta
1.44

Social Links

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:BVNRY) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners